Get started
Author

Diana Cao

18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease
2011 · M. T. Fodero-Tavoletti, N. Okamura, et al. · Brain · 343
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
2018 · Andrew C. Phillips, Erwin R. Boghaert, et al. · Molecular Cancer Therapeutics · 57
PDF
Comparison of Warfarin Pharmacogenetic Dosing Algorithms in a Racially Diverse Large Cohort
2010 · Jaekyu Shin, Diana Cao · Pharmacogenomics · 51
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2020 · Mark G. Anderson, Hugh D. Falls, et al. · Molecular Cancer Therapeutics · 49
Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa
2021 · Ingrid Julienne Georgette Burvenich, Yit Wooi Goh, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 27
Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
2020 · Puey-Ling Chia, Sagun Parakh, et al. · Pharmaceuticals · 18
PDF
Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers
2016 · Ingrid J. G. Burvenich, Fook-Thean Lee, et al. · EJNMMI Research · 18
PDF
An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy
2024 · Peter W. Janes, Adam C. Parslow, et al. · Cancers · 17
Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008
2013 · Ingrid J.G. Burvenich, Fook T. Lee, et al. · Clinical Cancer Research · 17
Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor
2016 · Ingrid J. G. Burvenich, William Farrugia, et al. · mAbs · 14
PDF
Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms
2015 · Sarah K. Baird, Angela Rigopoulos, et al. · APOPTOSIS · 13
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin
2021 · Hui K Gan, Sagun Parakh, et al. · Neuro-Oncology Advances · 12
PDF
Radiolabelling and evaluation of novel haloethylsulfoxides as PET imaging agents for tumor hypoxia
2012 · Evelyn Laurens, Shinn Dee Yeoh, et al. · Nuclear Medicine and Biology · 10
Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2
2023 · Christian Werner Wichmann, Ingrid Julienne Georgette Burvenich, et al. · Nuclear Medicine and Biology · 9
Altered Abundance of Barrier-Related Proteins in Brain Microvascular Endothelial Cells of the GL261 Mouse Model of Glioblastoma
2025 · Liam M Koehn, Diana Cao, et al. · Molecular Pharmaceutics · 5
Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia
2014 · Evelyn Laurens, Shinn Dee Yeoh, et al. · Nuclear Medicine and Biology · 5
Actr-55. Tumor Volume as a Predictor of Response to Anti-egfr Adc Abt-414
2018 · Hui Gan, Aidan Seow, et al. · Neuro-Oncology · 2
PDF
Characterisation of mAb104 Antibody–Drug Conjugates Targeting a Tumour-Selective HER2 Epitope
2025 · Sagun Parakh, Nhi Huynh, et al. · Cancers · 1
PDF
ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo.
2019 · Puey Ling Chia, Diana Cao, et al. · Journal of Clinical Oncology · 1
Abstract 743: ABT-806-derived antibody-drug conjugates (ADCs) inhibit growth of malignant mesothelioma in vivo
2018 · Puey Ling Chia, Diana Cao, et al. · Cancer Research · 1
An Exploratory Study of ABT-806, a Tumor-Specific Anti-EGFR Antibody, in Subjects with Recurrent or Metastatic Head and Neck and Other Squamous Cell Carcinomas
2026 · Hui K. Gan, Sagun Parakh, et al. · Cancers
Supplementary Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2023 · Mark G. Anderson, Hugh D. Falls, et al.
Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2023 · Mark G. Anderson, Hugh D. Falls, et al.
Supplementary Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2023 · Mark G. Anderson, Hugh D. Falls, et al.
Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2023 · Mark G. Anderson, Hugh D. Falls, et al.
Works count: 44
Citation count: 670
H-index: 12
I10-index: 13
Year
Topic
Type